Deucravacitinib is an oral selective tyrosine kinase 2 (TYK2) inhibitor that binds to the regulatory domain of TYK2, distinguishing it from other Janus kinase inhibitors. It is an active pharmaceutical ingredient used in pharmaceutical manufacturing.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1609392-27-9
6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3-carboxylic acid
pharmaceutical intermediate
Zinc(II) 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)pyridazine-3-carboxylate
pharmaceutical intermediate
6-chloro-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide
Research compound
SEL120-34A HCl
pharmaceutical raw material
Silodosin
pharmaceutical raw material
(R/S)-silodosin
pharmaceutical raw material
Desisopropyl butyl torsemide
pharmaceutical raw material
6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide
BZZKEPGENYLQSC-FIBGUPNXSA-N
[2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4